Capricor shares skyrocket as FDA agrees to review new Duchenne drug data

Capricor Therapeutics shares more than doubled in premarket trading on Friday after the company said the U.S. health regulator is willing to review new ​data on its experimental Duchenne muscular dyst...

本文内容来自外部来源，点击「继续访问」将跳转到原始发布站点。